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Background-—Predicting which patients are unlikely to beneﬁt from continuous ﬂow left ventricular assist device (LVAD) treatment
is crucial for the identiﬁcation of appropriate patients. Previously developed scoring systems are limited to past eras of device or
restricted to speciﬁc devices. Our objective was to create a risk model for patients treated with continuous ﬂow LVAD based on the
preimplant variables.
Methods and Results-—We performed a retrospective analysis of all patients implanted with a continuous ﬂow LVAD between
2006 and 2014 at the University of Pennsylvania and included a total of 210 patients (male 78%; mean age, 5615; mean follow-
up, 465486 days). From all plausible preoperative covariates, we performed univariate Cox regression analysis for covariates
affecting the odds of 1-year survival following implantation (P<0.2). These variables were included in a multivariable model and
dropped if signiﬁcance rose above P=0.2. From this base model, we performed step-wise forward and backward selection for other
covariates that improved power by minimizing Akaike Information Criteria while maximizing the Harrell Concordance Index. We
then used Kaplan–Meier curves, the log-rank test, and Cox proportional hazard models to assess internal validity of the scoring
system and its ability to stratify survival. A ﬁnal optimized model was identiﬁed based on clinical and echocardiographic
parameters preceding LVAD implantation. One-year mortality was signiﬁcantly higher in patients with higher risk scores (hazard
ratio, 1.38; P=0.004). This hazard ratio represents the multiplied risk of death for every increase of 1 point in the risk score. The
risk score was validated in a separate patient cohort of 260 patients at Columbia University, which conﬁrmed the prognostic utility
of this risk score (P=0.0237).
Conclusion-—We present a novel risk score and its validation for prediction of long-term survival in patients with current types of
continuous ﬂow LVAD support. ( J Am Heart Assoc. 2018;7:e006408. DOI: 10.1161/JAHA.117.006408.)
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M echanical assist devices have emerged as an estab-lished therapeutic option for patients with end-stage
heart failure.1 Predicting which patients are unlikely to beneﬁt
from left ventricular assist device (LVAD) implantation is
essential in order to identify appropriate patients while
excluding those considered futile. The need for risk prediction
before LVAD implantation has led to the recognition of various
risk factors, including age, low serum albumin, low platelet
count, impaired renal function, and high international normal-
ized ratio,2,3 and to the development of several risk scores for
short-term (90 days) mortality.2,3 Lietz et al2 retrospectively
analyzed preoperative clinical data of patients treated with
pulsatile LVAD (HeartMate XVE) as destination therapy and
evaluated a risk scoring system consisting of 9 risk factors for
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estimation of 90-day mortality.3 Cowger et al generated the
HeartMate II Risk Score (HMRS) for predicting LVAD candi-
date 90-day mortality.3 Although the HeartMate II Risk Score
was originally created to predict 90-day survival, it was also
found to predict risk several months after LVAD implant.3
Although the importance of risk proﬁle is clear, there is
currently no validated risk score estimating the long-term
survival of continuous ﬂow LVAD (cf-LVAD) patients. Our goal
was to create a risk model predicting the long-term survival of
LVAD patients based on the patients’ preimplant characteristics.
Methods
Study Design
A derivation sample was selected from a single-center retro-
spective cohort of all 571 patients implantedwith an LVADat the
Hospital of the University of Pennsylvania from 2006 to 2014.
Within this cohort, we analyzed only those patients who were
implanted with a cf-LVAD (n=223), which included Heartmate II
(St Jude Medical Ltd, St. Paul, MN) and HVAD (HeartWare Ltd,
Framingham, MA) models. We excluded all patients who were
simultaneously implanted with a right ventricular assist device
(n=13), leaving a ﬁnal study sample of 210 patients.
A validation sample was then similarly constructed retro-
spectively from an independent set of 260 patients who
underwent LVAD implantation at Columbia University’s New
York-Presbyterian Hospital from 2006 to 2013. Patients in the
validation cohort were similarly excluded for simultaneous
RVAD implantation and restricted to cf-LVADs.
Cumulative survival within 1 year after LVAD implantation
was the primary outcome. Patients who underwent heart
transplant before 1 year contributed person-time at risk up to
the time of transplant, but were afterward right censored from
all analyses. The institutional review board of both institutions
approved the study protocol.
Subjects’ informed consent was waived. The de-identiﬁed
data, analytical methods, and study materials that support the
ﬁndings of this study are available from the corresponding
author upon reasonable request.
Statistical Analysis
The derivation data set contained data from 155 independent
clinical variables (Table S1). Among these, 17 variables had a
plausible inﬂuence on 1-year mortality and <25% missing data.
Parameters were either continuous (eg, platelet count), ordinal
(eg, level of right ventricular dysfunction), dichotomous (eg,
diabetic or not diabetic), or categorical (eg, race). Body mass
index (BMI) was a continuous variable treated as a spline term
for BMI <20, 20 to 25, or >25. Right ventricular dysfunction,
aortic insufﬁciency, mitral regurgitation, and tricuspid regurgi-
tation were assessed at the University of Pennsylvania
Echocardiography laboratory as absent, mild, moderate, or
severe.
Each of these variables was tested for its univariate
association with 1-year mortality in a Cox proportional hazard
regression and was dropped from the initial model for P>0.2.
Remaining variables were entered into a multivariate Cox
proportional hazard model and eliminated for P>0.2. From this
baseline model, we applied step-wise forward selection of any
variables that improved model explanatory power based on
area under the curve (AUC, assessed by Harrel’s C-Index)4 so
long as this did not deteriorate model likelihood ratio
(assessed by Akaike Information Criteria [AIC]5 ie, compared
with the baseline model before step-wise forward regression,
if the AUC remained the same or worse, no increase in AIC
was allowed. If the AUC improved, we tolerated an increase in
the AIC by no more than 0.5%. Any further increase in AIC was
considered detrimental to the model and led to exclusion of
that variable). Spline terms were generated where appropriate
and included if model explanatory power improved. Potential
interactions were assessed between each covariate in the
ﬁnal multivariable model. Analysis was performed using Stata
software (version 12.0; StataCorp LP, College Station, TX).
Score Generation and Survival Analysis
Each independent variable in the ﬁnal model had an
associated hazard ratio from the Cox proportional hazard
Clinical Perspective
What Is New?
• Previously developed scoring systems are limited to past
eras of device or restricted to speciﬁc devices, and there are
currently no validated long-term risk models for this
population.
• In this study, we aimed to generate a long-term risk model
for patients undergoing ventricular assist device implanta-
tion.
• In this retrospective analysis, we analyzed various param-
eters at preimplant and created a risk model for long-term
mortality.
• The risk score was then validated in a separated patient
cohort at Columbia University.
• An online calculator was created for easier application of
the formula (http://penncolumbiariskscore.weebly.com)
What Are the Clinical Implications?
• Our novel and simple risk model for prediction of long-term
mortality based on preimplant characteristics may improve
patient selection and will allow identifying high-risk patients.
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regression. These ratios were log transformed to a linear scale
and then directly imported into a novel score that added each
individual component, thereby weighting the relative impor-
tance of each contributing covariate by its hazard ratio.
Patients were divided into tertiles of risk score that
corresponded to a “lowest risk,” “moderate risk,” and “highest
risk” group. Cumulative survival between these 3 groups was
assessed up to 1 year after LVAD implantation using Kaplan–
Meier analysis, again right censoring for any patients that
were heart transplanted before the 1-year mark. Differences
in the distribution of survival between the 3 tertiles were
assessed with the log-rank test.
Model Validation
This novel risk score was then applied to all patients within
the validation cohort at Columbia University Medical Center
for an independent assessment of score performance. Model
ﬁt was assessed with the AUC, and cumulative survival
distributions between tertiles of risk score were assessed
with Kaplan–Meier analysis and the log-rank test.
Results
Model Derivation and Score Generation
A total of 210 patients were included in our derivation cohort
who underwent implantation of a continuous ﬂow LVAD
without concurrent right ventricular assist device. One
hundred eighty-two of these devices were Heartmate II (87%)
and 28 were HVAD HeartWare (13%). Seventy percent of the
patients were male, 48% white, and 20% black, with average
age 56 at time of implant. Initial indications for LVAD were
bridge to transplant (37%), bridge to decision (8%), destination
therapy (52%), or bridge to recovery (3%). One-year mortality
among all LVAD patients who did not undergo heart transplant
was 29%. Table 1 summarizes the baseline characteristics of
the study cohort at the University of Pennsylvania and the
validation cohort at Columbia University Medical Center.
Exploratory analysis starting with 17 plausible covariates
demonstrated 7 variables associated with mortality (P<0.2) in
Cox proportional hazard models (Table 2). All 7 of these
variables were then assessed for signiﬁcance in a multivariate
Cox proportional hazard model. Two variables, age and serum
creatinine, retained signiﬁcance (P<0.2) in the multivariate
model and formed our base model (Table 3).
From this base model, we performed step-wise forward
selection with each of the previous 17 covariates, assessing
the impact of each variable on 2 measures of model
explanatory power: AIC and AUC. An additional 4 variables
(BMI, total serum bilirubin, right ventricular dysfunction, and
aortic insufﬁciency) were found to improve AUC without
detriment to AIC, and they were added to the base model.
Thus, the ﬁnal model included: age, serum creatinine, and
total bilirubin assessed as continuous variables; BMI as a
spline variable for low BMI (<20), normal BMI (20 to 25), and
elevated BMI (>25); and 2 echocardiographic parameters—
right ventricular dysfunction and aortic insufﬁciency—
assessed as mild, moderate, or severe. The ﬁnal model had
an AIC of 437 and an AUC of 73%. No covariates had
signiﬁcant interactions with one another in the ﬁnal model.
From this ﬁnal multivariable model, we generated a novel
score directly extracted from the model’s log-transformed
hazard ratios (Figure 1). This ensured that scores would be
proportional to their weight in the model. An online calculator
was created for easier application of the formula (http://pe
nncolumbiariskscore.weebly.com). In our cohort, scores had a
range of 1.8 to 10.1, mean 5.91.35, and median 6.0
(Figure 2). Stratiﬁed by indication, the score among patients
who were bridge to transplant had range 1.7 to 8.4, mean 5.8,
and median 6.0; patients who were destination therapy had
range 3.3 to 10.1, mean 6.3, and median 6.3; patients who
were bridge to recovery had range 2.4 to 7.3, mean 5.1, and
median 5.4; and patients who were bridge to decision had
range 3.3 to 6.9, mean 5.4, and median 5.5. Destination
Table 1. Baseline Characteristics of Derivation Cohort
(University of Pennsylvania) and Validation Cohort (Colombia
University)
Characteristic
University of
Pennsylvania
(n=210)
Columbia
University
(n=260) P Value
Age, meanSD 5615 5714 0.89
Sex (% male) 78 81 0.42
Race, %
White 48 62 0.002
Black 20 20 1
Other 32 18 0.26
Diabetic (% HgA1c >6.5) 47 37 0.029
VAD indication, %
Bridge to transplant 37 69 <0.001
Destination therapy 52 27 <0.001
Bridge to decision 8 3 0.016
Bridge to recovery 3 1 0.11
Body mass index, meanSD 28.06.7 275 0.74
Active tobacco
smoker within 1 year, %
40 42 0.66
Hyperlipidemia, % 65 49 <0.001
Ejection fraction, meanSD 167 176 0.81
HgA1c indicates glycated hemoglobin; VAD, ventricular assist device.
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therapy patients tended to have a higher score on average,
though a comparison of means across indication by ANOVA
did not meet threshold for signiﬁcance (P=0.052), albeit with
a reduction in power for a subgroup analysis.
Survival Analysis
Figure 3 shows the cumulative survival curve using the novel
risk score. Patients were divided into tertiles of risk score,
Table 2. Univariate Association With Mortality in Separate
Cox Proportional Hazard Models
Covariate Hazard Ratio P Value
BMI <20 0.8 0.48
BMI 20 to 25 1.22 0.91
BMI >25 0.91 0.86
Sex 1 0.99
Age* 1.04* <0.001*
Type 2 diabetes mellitus 0.87 0.59
Race
White 1.04 0.84
Black 0.64 0.21
Other 1.05 0.85
Atrial fibrillation 1.19 0.47
Cerebrovascular accident 0.66 0.27
Coronary artery disease* 1.64* 0.047*
Right ventricular dysfunction 1.07 0.34
Tricuspid regurgitation 0.94 0.38
Mitral regurgitation* 0.9* 0.11*
Aortic insufficiency* 1.18* 0.031*
Ejection fraction 0.99 0.94
Hemoglobin, g/dL* 0.87* 0.044*
Platelet count 0.99 0.34
Serum creatinine* 1.34* 0.005*
Total serum bilirubin* 1.23* 0.096*
Log rank, P=0.005. BMI indicates body mass index in kg/m2.
*P<0.20.
Table 3. Multivariate Association With Mortality in a Single
Cox Proportional Hazard Models
Covariate Hazard Ratio P Value
Age* 1.05* 0.001*
Coronary artery disease 1.35 0.396
Mitral regurgitation 0.97 0.75
Aortic insufficiency 1.02 0.82
Hemoglobin, g/dL 1.01 0.88
Serum creatinine* 1.71* 0.003*
Total bilirubin 1.17 0.28
*P<0.20.
Score < 6 – Low Risk
Score 6< to  <6.7  - Medium risk
Score >6.7 – High risk
Figure 1. The Penn—Columbia Risk Score. The preimplant
clinical and echocardiographic parameters utilized to generate the
Penn—Columbia risk score with weighted value of each variable
in tabulation of risk score. The additive result generated scores
below 6, thus associated with low risk and favorable 1-year
survival, scores between 6 and 6.7, associated with intermediate
risk, and scores above 6.7 associated with high risk and
unfavorable 1-year survival (also seen in Figure 3). For example:
A 64 year old patient with creatinine level of 1.6 mg/dl and total
bilirubin of 1.5 mg/dl. His BMI was 28 and he has moderate right
ventricular dysfunction and mild aortic insufﬁciency. This patient’s
score is: 64*0.064+1.6*0.541+1.5*0.214+28*0.047+0.165+
0.216=6.9796. BMI indicates body mass index. Creatinine in
mg/dl, Total Bilirubin in mg/dl.
Figure 2. Distribution of the Novel Score within the patient
cohort. This graph shows the distribution of the cohort patients
across the risk score spectrum.
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making a low risk (2.50–5.95), medium risk (5.96–6.74), and
high risk (6.75–10.10) group. As seen in the graph, 1-year
mortality was signiﬁcantly increased in the highest risk group
(50%) relative to the low- (21%) and medium-risk (23%) groups.
The log-rank test comparing survival distributions among the
3 groups was statistically signiﬁcant with P<0.001. Risk score
was not associated with LVAD-associated complications
occurring during the ﬁrst year after implantation, such as
acute right ventricular failure, LVAD thrombosis, or gastroin-
testinal bleeding.
Model validation
The novel risk score derived from the LVAD cohort at the
University of Pennsylvania was then applied to LVAD cohort
from Columbia University Medical Center. Again, mortality in
the highest risk group was greater than the low- or medium-
risk groups with P=0.02 by the log rank test (Figure 4).
Discussion
According to the seventh annual report of the INTERMACS
(Interagency Registry for Mechanically Assisted Circulatory
Support),1 the number of patients treated with continuous
ﬂow ventricular assist device continue to rise, with more than
2000 implants per year occurring in the United States alone.1
With the increasing number of patients treated with durable
assist device therapy, patient selection is essential to
determine which patients will beneﬁt from this therapy. In
the current study, we generated a novel risk score, based on a
combination of preimplant clinical, laboratory, and echocar-
diographic characteristics, identifying patients at high risk of
1-year mortality with cf-LVAD support. Importantly, our risk
model was validated at Columbia University Medical Center in
a similar patient cohort.
All risk scores published so far focused on the short-term
survival (ie, 90-day mortality).2,3 The Lietz risk score2 was the
ﬁrst risk score to predict the short-term outcomes of patients
treated with ﬁrst-generation, pulsatile ﬂow, ventricular assist
devices.2 Given that the vast majority of the patients on LVAD
support are currently being treated with second- and third-
generation continuous ﬂow devices and these devices have
different outcome proﬁle compared to the ﬁrst-generation
devices, the Lietz’s risk score should not be used in the
current practice. The HeartMate II risk score used the data
that were collected in the HeartMate II trial.3 It was originally
planned to predict the 90-day survival of patients with
HeartMate II assist device. Based on this risk score, patients
were divided into 3 groups based on 90-day mortality rate:
low risk with 4%, medium risk with 16%, and high risk with
29%.3 Interestingly, the differences between the groups
remained signiﬁcant after a year.3 Thomas et al tried to
validate the HMRS in a cohort of patients treated at the
Columbia University Medical Center.6 However, according to
their ﬁndings, patient survival was similar regardless of HMRS
stratiﬁcation and HMRS was not valid in predicting 90-day
survival in this large-volume academic center.6 Small cohorts
validated the use of the Seattle Heart Failure model7 and the
European System for Cardiac Operative Risk Evaluation II
(EuroSCORE II)8 as predictors of survival in LVAD candidates.
Most variables used in our risk model have been proven to
be associated with poor outcomes. Atluri et al analyzed the
INTERMACS national registry and divided the patients into 2
age groups (<70 and ≥70 years). Not surprisingly, advanced
age was found to be a predictor of increased mortality after
cf-LVAD implantation.9 Age was also found to be a signiﬁcant
predictor both in the Lietz2 as well in the HeartMate II risk
scores.3 Creatinine was signiﬁcant in the HeartMate II model,
but not in Lietz risk score, and bilirubin was not signiﬁcant in
Log rank p = 0.005
Figure 3. Twenty-four months survival distributions by tertile of
risk score in the derivation cohort. Kaplan–Meier survival curve
representing the survival distributions among the cohort, strati-
ﬁed by tertile. Log rank, p=0.005.
Log Rank p=0.02
Figure 4. Columbia University Medical Center survival curve
divided according to the risk score. Kaplan–Meier survival curve
representing the survival distributions of the validation cohort
stratiﬁed by tertile. Log rank, P=0.02.
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both studies.2,3 Interestingly, our model uses 2 echocardio-
graphic parameters: right ventricular dysfunction and aortic
insufﬁciency (AI). AI in patients supported with LVAD may lead
to a circulatory loop, leading to ineffective forward ﬂow and
inadequate organ perfusion. The effect of AI on survival is not
clear. Cowger et al analyzed the effect of the postimplant AI
on survival of 166 patients treated with durable LVAD
support.10 According to their results, postimplant develop-
ment of AI did not affect survival or the risk of mitral
regurgitation.10 Our study is the ﬁrst to show that preimplant
AI may affect long-term survival. Right ventricular function has
been associated with increased risk of postimplant acute right
ventricular failure and impaired survival.11 However, no risk
model in the past had used preimplant right ventricular
dysfunction as a parameter.
Our risk score is the ﬁrst to predict long-term outcome in
patients treated both with HeartMate II and HeartWare
devices. The main limitation of our model is being a
retrospective single-center trial. However, validating the
model in another large-volume academic center, with different
patient characteristics, allows us to conﬁdently assume that
this is an accurate tool for prediction of long-term survival of
this population. Moreover, our model, unlike the HeartMate II
risk model, evaluates patients’ not on clinical trials and
represents the “real-life” management of LVAD patients.
Another advantage of our risk model is in its simplicity given
that it uses basic clinical and echocardiographic parameters
that can be estimated by every local cardiologist. Needless to
say, as a retrospective analysis it is always possible that the
risk-score variables actually reﬂect more-proximal causes of
increased risk that are not as easily measured such as
duration of heart failure. However, our risk score variables are
absolute and can be easily obtained for every candidate. As
such, our risk score is an important bedside tool that is well
validated to aid in—but not replace—clinical judgment for
patients being considered for LVAD implantation. It is likely
that the “PENN—COLUMBIA risk score” could be applied to
the INTERMACS registry, but currently not applicable based
on the variables entered. Enhanced data collection and risk
assessment is desirable.
In conclusion, we present a novel and validated risk model
predicting the long-term survival of LVAD patients based on
patients’ preimplant characteristics. Predicting which patients
are at high risk may improve patients’ selection on the one
hand and allow closer follow-up of patients at increased risk
for unfavorable outcome.
Disclosures
Dr Birati received fellowship and research support by Heart-
Ware Ltd and is a consultant for Luitpold Pharmaceuticals, Inc.
Dr Goldberg is a consultant for Thoratec, St. Jude, and
Respircardia. Dr Margulies received research grant support
from Juventis Therapeutics, Celladon Corporation, Thoratec
Corporation, and Merck and Co, Inc. He is also a consultant for
Janssen, Merck, Pﬁzer, Ridgetop Research, AstraZeneca, and
NovoNordisk. Dr Rame received research grant support from
Thoratec Corporation and HeartWare Ltd. Drs Hanff, Maldon-
ado, Grandin, Kennel, Mazurek, Phillips, Vorovich, Seigerman,
Acker, Naka, Wald, Jessup, Atluri, and Schulze have no
disclosures.
References
1. Kirklin JK, Naftel DC, Pagani FD, Kormos RL, Stevenson LW, Blume ED, Myers
SL, Miller MA, Baldwin JT, Young JB. Seventh INTERMACS annual report:
15,000 patients and counting. J Heart Lung Transplant. 2015;34:1495–1504.
2. Lietz K, Long JW, Kfoury AG, Slaughter MS, Silver MA, Milano CA, Rogers JG,
Naka Y, Mancini D, Miller LW. Outcomes of left ventricular assist device
implantation as destination therapy in the post-REMATCH era: implications for
patient selection. Circulation. 2007;116:497–505.
3. Cowger J, Sundareswaran K, Rogers JG, Park SJ, Pagani FD, Bhat G, Jaski B,
Farrar DJ, Slaughter MS. Predicting survival in patients receiving continuous
ﬂow left ventricular assist devices: the HeartMate II risk score. J Am Coll
Cardiol. 2013;61:313–321.
4. Lloyd-Jones DM. Cardiovascular risk prediction: basic concepts, current status,
and future directions. Circulation. 2010;121:1768–1777.
5. Forster MR. Key concepts in model selection: performance and generalizabil-
ity. J Math Psychol. 2000;44:205–231.
6. Thomas SS, Nahumi N, Han J, Lippel M, Colombo P, Yuzefpolskaya M, Takayama
H, Naka Y, Uriel N, Jorde UP. Pre-operative mortality risk assessment in patients
with continuous-ﬂow left ventricular assist devices: application of the HeartMate
II risk score. J Heart Lung Transplant. 2014;33:675–681.
7. Ketchum ES, Moorman AJ, Fishbein DP, Mokadam NA, Verrier ED, Aldea GS,
Andrus S, Kenyon KW, Levy WC. Predictive value of the Seattle Heart Failure
Model in patients undergoing left ventricular assist device placement. J Heart
Lung Transplant. 2010;9:1021–1025.
8. Menon AK, Mechelinck M, Unterkoﬂer J, Goetzenich A, Autschbach R, Tewarie
L, Moza A. Predictive value of EuroSCORE II in patients undergoing left
ventricular assist device therapy. Thorac Cardiovasc Surg. 2016;64:475–482.
9. Atluri P, Goldstone AB, Kobrin DM, Cohen JE, MacArthur JW, Howard JL, Jessup
ML, Rame JE, Acker MA, Woo YJ. Ventricular assist device implant in the
elderly is associated with increased, but respectable risk: a multi-institutional
study. Ann Thorac Surg. 2013;96:141–147.
10. Cowger JA, Aaronson KD, Romano MA, Haft J, Pagani FD. Consequences of
aortic insufﬁciency during long-term axial continuous-ﬂow left ventricular
assist device support. J Heart Lung Transplant. 2014;33:1233–1240.
11. Todaro MC, Khandheria BK, Paterick TE, Umland MM, Thohan V. The practical
role of echocardiography in selection, implantation, and management of
patients requiring LVAD therapy. Curr Cardiol Rep. 2014;16:468.
DOI: 10.1161/JAHA.117.006408 Journal of the American Heart Association 6
Predicting Outcome of LVAD Patients Birati et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
  
 
 
 
SUPPLEMENTAL MATERIAL 
 
 
 
Table S1. List of all Independent Clinical Variables Considered in the Derivation Dataset. 
 Demographics and Medical History, Pre-implantation 
  
Sex  
Race  
American Society of Anesthesia (ASA) Score 
Weight 
Height 
Body Mass Index 
History of coronary artery disease 
History of pulmonary hypertension 
History of COPD 
History of diabetes mellitus 
History of smoking 
History of hypertension 
History of hyperlipidemia 
History of carotid stenosis 
History of atrial fibrillation 
History of cerebrovascular accident 
History of chronic renal insufficiency 
History of renal failure requiring dialysis 
Other important past medical history 
Etiology of patient's heart failure 
Reason for LVAD exchange 
Patient has progressive CHF 
Patient has end-stage heart failure 
Patient has severe coronary artery disease 
Patient has increasing shortness of breath or paroxysmal nocturnal dyspnea 
Patient was transferred from an outside hospital the same admission as LVAD implantation 
LVAD indication (i.e. bridge to transplant, bridge to decision, destination, or bridge to 
recovery) 
Duration of patient's heart failure 
History of gastrointestinal bleeding 
History of ventricular arrythmia 
Type of Prior stroke (hemorrhagic versus ischemic) 
History of venous thromboembolism 
Patient is insulin dependent 
INTERMACS Class at time of LVAD implantation 
Patient on Beta Blocker 
Patient on ACE inhibitor or Angiotensin Receptor Blocker 
Patient on aldosterone antagonist 
Patient on nitrates 
Patient on hydralazine 
Patient on digoxin 
Patient on diuretic 
Patient on vasopressor 
Patient on an antiarrhythmic medication 
Patient taking an oral pulmonary vasodilator 
Patient on aspirin 
Patient on other anti-platlet agents 
Patient on anticoagulation 
QRS duration on pre-LVAD ECG 
Implantable cardioverter defibillator present 
Pacemaker present 
Biventricular pacemaker present 
  
Echocardiographic Variables, Pre-Implantation 
  
Echo date 
Degree of right ventricular dysfunction 
Degree of tricuspid regurgitation 
Degree of mitral regurgitation 
Degree of aortic insufficiency 
LV ejection fraction 
Patent foramen ovale present 
Left ventricular end-diastolic diameter 
LV end-systolic diameter 
Left atrial diameter from parasternal long axis 
Left atrial size (qualitative) 
Right ventricular systolic pressure 
Estimated right atrial pressure 
Estimated pulmonary arterial systolic pressure (PASP) 
Tricuspid annular planar systolic excursion (TAPSE) 
Interventricular septal flattening 
Interventricular septal position 
  
Hemodynamics, Pre-implantation 
  
Date of hemodynamic measurements 
Heart rate 
Systolic blood pressure 
Diastolic blood pressure 
Mean arterial blood pressure 
Central venous pressure 
Pulmonary artery systolic pressure 
Pulmonary artery diastolic pressure 
Mean pulmonary arterial pressure 
Cardiac output 
Cardiac index 
Pulmonary artery oxygen saturation (SvO2) 
Stroke volume index 
Right ventricular stroke work index 
Patient on milrinone at time of measurement 
Patient taking oral sildenafil 
Patient receiving inhaled prostacyclin 
  
Laboratory Values, Pre-implantation 
  
White blood cell count 
Hemoglobin 
Platelets 
Blood urea nitrogen 
Creatinine 
Sodium 
Potassium 
Carbon Dioxide 
Aspartate triaminase (AST) 
Alamine triaminase (ALT) 
Total bilirubin 
Sodium Bicarbonate 
Lactic acid 
Albumin 
Prealbumin 
INR 
PTT 
Lactate Dehydrogenase 
Plasma free hemoglobin 
Haptoglobin 
Hemoglobin A1c 
  
Implantation Variables 
  
LVAD implantation date 
Age at implant 
LVAD, RVAD, BiVAD, or total artificial heart implanted 
LVAD model 
Did patient undergo LVAD exchange 
Did patient receive a delayed RVAD 
Number of days between LVAD and RVAD 
Type of RVAD 
Intubation required pre-operatively 
ECMO required pre-operatively 
Intra-aortic balloon pump required pre-operatively 
Inotropes required pre-operatively 
CABG performed intra-operatively 
Tricuspid valve repair performed intra-operatively 
Mitral valve repair performed intra-operatively 
Aortic valve closure performed intra-operatively 
Aortic valve repair performed intra-operatively 
Aortic valve replacement performed intra-operatively 
Cardiopulmonary Bypass time 
Cross Clamp time 
Surgical approach 
Prior sternotomy present 
Post-implant cryoablation 
Factor 7 given intra-operatively 
Units of fresh-frozen plasma given intra-operatively 
Units of packed red blood cells given intra-operatively 
Units of platelets given intra-operatively 
Time to extubation 
ICU length of stay 
Milrinone present immediately post-operatively 
Date milrinone started 
Dose of milrinone post-operatively 
Date milrinone stopped 
Neosynephrine present immediately post-operatively 
Date neosynephrine started 
Dose of neosynephrine 
Date neosynephrine stopped 
Vasopressin present immediately post-operatively 
Date vasopressin started 
Dose of vasopressin 
Date vasopressin stopped 
Levophed present immediately post-operatively 
Date levophed started 
Dose of levophed 
Date levophed stopped 
Epinephrine present immediately post-operatively 
Date epinephrine started 
Dose of epinephrine 
Date epinephrine stopped 
 
